ASND Quote, Trading Chart, Ascendis Pharma A/S
home / stock / asnd / asnd quote
$130.25 Last:
1.58% Change Percent:
$127.36 Open:
$130.25 Previous Close:
$130.325 High:
$125.96 Low:
203,313 Volume:
06/11/2021 04:42:19 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
ASND Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-06-11 | 127.36 | 130.25 | 130.325 | 125.96 | 203,313 |
| 2021-06-10 | 131.86 | 128.22 | 132.02 | 127.38 | 203,358 |
| 2021-06-09 | 131.3 | 130.9 | 132.78 | 129.82 | 132,689 |
| 2021-06-08 | 131.19 | 130.83 | 131.64 | 129 | 125,715 |
| 2021-06-07 | 129.7 | 131.24 | 133.5 | 128.36 | 171,093 |
| 2021-06-04 | 131.74 | 130.36 | 131.98 | 127.48 | 90,624 |
| 2021-06-03 | 126.72 | 130.82 | 131.46 | 124.05 | 176,352 |
| 2021-06-02 | 132.71 | 128.94 | 134.8 | 123.27 | 517,544 |
| 2021-06-01 | 135.33 | 133.53 | 136.45 | 127.34 | 329,673 |
| 2021-05-31 | 136.8 | 134.38 | 140.92 | 133.48 | 247,936 |
| 2021-05-28 | 136.8 | 134.38 | 140.92 | 133.48 | 247,936 |
| 2021-05-27 | 134.28 | 136.19 | 136.21 | 133 | 284,592 |
| 2021-05-26 | 133.54 | 133.77 | 136.37 | 131.38 | 213,316 |
| 2021-05-25 | 134.85 | 132.59 | 134.85 | 131.56 | 209,509 |
| 2021-05-24 | 139 | 135.09 | 139 | 134.33 | 146,682 |
| 2021-05-21 | 138.59 | 137.23 | 138.83 | 135.14 | 133,179 |
| 2021-05-20 | 135.22 | 137.47 | 142 | 133.895 | 171,869 |
| 2021-05-19 | 137.43 | 134.62 | 141.7 | 132.54 | 229,791 |
| 2021-05-18 | 135 | 138.12 | 141.3 | 133.665 | 258,900 |
| 2021-05-17 | 131.92 | 135.63 | 135.99 | 130.02 | 100,954 |
News, Short Squeeze, Breakout and More Instantly...
-
COPENHAGEN, Denmark, June 11, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that address unmet medical needs, today announced that the U.S. Food and Drug Administra...
-
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial PR Newswire 1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National...
-
Image source: The Motley Fool. Ascendis Pharma A/S (NASDAQ: ASND) Q1 2021 Earnings Call May 27, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript